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CURRENT CHEMOTHERAPY AND MONOCLONAL ANTIBODY USE 
PATTERNS IN METASTATIC COLORECTAL CANCER IN WESTERN 
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OBJECTIVES: Treatment outcomes improved in metastatic colorectal cancer (mCRC) 
due to the introduction of the monoclonal antibodies (mAb) in combination with 
chemotherapy. This study described current treatment patterns of chemotherapy and 
mAbs in clinical practice in 4 EU countries. METHODS: This cohort study used 
physician-surveyed data from the LifeLinkTM Oncology Analyzer Database for mCRC 
patients in four EU countries (France, Germany, Italy, and Spain). All patients aged 
≥21 years at mCRC diagnosis were included. Treatment patterns in 2009 were exam-
ined descriptively by lines of therapy. RESULTS: The study sample includes 
2734 mCRC patients (61% male, median age category 61–70 years) with 862, 656, 
567, and 649 from France, Germany, Italy, and Spain, respectively. In 1st-line, more 
patients received FOLFOX-containing regimens than FOLFIRI-containing regimens in 
Germany (42% vs. 30%) and Spain (25% vs. 16%), while in Italy and France, the 
reverse was true (Italy: 34% FOLFIRI vs. 29% FOLFOX: France: 26% vs. 19%). In 
2nd-line, more patients received FOLFIRI-containing regimens than FOLFOX-con-
taining regimens in Germany (36% vs. 18%), Italy (29% vs. 14%), and Spain (34% 
vs. 6%), while similar proportions of FOLFOX and FOLFIRI were used in France 
(18% vs. 15%). In 1st line, Bevacizumab (Bmab) was administered to 44% of patients 
in Italy, 42% in France, 37% in Germany, and 30% in Spain, while Cetuximab 
(Cmab) use ranged from 14% in Spain to 7% in Italy. In 2nd-line, Bmab was used in 
37% of the patients in Germany, 38% in France, 33% in Italy, and 30% in Spain, 
while Cmab was used in 30% of the patients in Spain, followed by 26% in Italy, 20% 
in Germany and 17% in France. CONCLUSIONS: FOLFOX- and FOLFIRI-based 
regimens are common standard of care chemotherapies, and monoclonal antibodies 
are routinely combined with these chemotherapies.
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IN GREECE AND THEIR IMPACT ON PATIENTS AND CARERS
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OBJECTIVES: Previous studies (NSPH 2008, 2009) demonstrated that clustering of 
oncology resources exceeds the spatial concentration pattern of health-care services in 
Greece, thus resulting to substantial cross-regional ﬂ ows of cancer patients. The objec-
tive of this study was to assess the impact of geographic accessibility on patients when 
selecting care and during treatment for cancer. METHODS: Face-to-face interviews 
with 106 patients diagnosed with cancer from three specialized anticancer hospitals 
(two Athens and one Thesaloniki). Questionnaire was designed by a specialized Delphi 
panel of the NSPH to capture patient preferences. Median patient age was 54.5 years. 
Data were analyzed using SPSS v.15.0. RESULTS: Patients across the board choose 
their hospital on the basis of specialization (50%), physician reference (41.5%), and 
hospital reputation (35.8%). Sixty-three percent of patients face access barriers, most 
commonly cost of health-care services (44.3%), distance from place of residence 
(37%), and demand on time (33%). 76.4% of patients return to place of residence at 
treatment intervals and 43.4% immediately after treatment. To receive treatment, 
23.6% stay at homes of relatives, 14.2% at hotels, and 1% in hospital-owned hos-
pices. Fifty percent of patients undergo treatment cycles repeating every 15–30 days. 
Patients travel predominately by own car (48.1%). 4.7% travel by taxi reimbursed by 
their insurance fund and 1% by hospital ambulance. 84% of patients travel accom-
panied by one or more carers. At treatment intervals, only 8% of patients are sup-
ported by physicians at place of residence. CONCLUSIONS: Signiﬁ cant cross-regional 
ﬂ ows of cancer patients to access adequate treatment lead to substantial direct and 
indirect costs for patients and their carers in a strained ﬁ nancial environment. Patients 
also face signiﬁ cant gaps in integrated support during treatment intervals. a shift in 
the organization of cancer services is essential for the system to be responsive to 
expressed patient needs especially during treatment.
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OBJECTIVES: Bone metastases occur in up to 75% of patients with advanced breast 
cancer. Skeletal complications of bone metastases include pathologic fracture, spinal 
cord compression, and surgery and radiation to bone. In a recently completed trial of 
breast cancer patients with bone metastases, denosumab, a fully human monoclonal 
anti-RANKL antibody, was superior to zoledronic acid (ZA) in delaying/preventing 
skeletal related events (SRE). METHODS: Eligible patients (N = 1026, denosumab; 
N = 1020, ZA) received monthly subcutaneous denosumab 120 mg or intravenous 
ZA 4 mg in a double-bind, double-dummy design. Health resource utilization (HRU) 
data, excluding protocol-speciﬁ ed visits, were collected from all randomized patients 
monthly through end of study (median duration 17 months, both groups). RESULTS: 
Comparing patients who experienced any on-study SRE (n = 315, denosumab; n = 
372, ZA) with patients without an on-study SRE, a greater proportion reported at 
least one radiation oncology unit visit (22.9% vs. 8.7%), clinic visit (75.5% vs. 
71.1%), and inpatient hospitalization (62.9% vs. 48.6%). The mean number of clinic 
visits and inpatient hospitalizations was also greater for patients who experienced an 
on-study SRE. A between-treatment group comparison of denosumab versus ZA 
demonstrated that for patients with one or more clinic visits who experienced any 
on-study SRE, the denosumab group had 10% fewer mean clinic visits compared with 
the ZA group (15.5 vs. 17.2 visits). Additionally, mean radiation oncology clinic visits 
were decreased by 32% in the denosumab compared with the ZA group (4.2 vs. 6.2 
visits) and mean inpatient hospitalizations were decreased by 12% (3.7 vs. 4.2 hospi-
talizations). CONCLUSIONS: Regardless of treatment group, patients who had an 
on-study SRE had greater HRU compared with patients not experiencing an on-study 
SRE. In this study, among those with any on-study SRE, patients treated with deno-
sumab had fewer clinic visits, radiation oncology unit visits, and inpatient hospitaliza-
tions compared to patients treated with zoledronic acid.
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MEDICAL RESOURCES UTILIZATION OF FIVE MOST PREVALENT 
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OBJECTIVES: We want to study the real cost structure of cancer treatment using the 
National Health Insurance Research Database (NHIRD) from Taiwan. METHODS: 
This study adopted a retrospective observational design and the data were retrieved 
from the NHIRD, which is managed by the National Health Research Institutes 
(NHRI). We used descriptive statistical methods to display data and time trend. 
RESULTS: The number of patients with these ﬁ ve cancers showed an increasing trend 
in these 7 years. Breast cancer had the highest annual increase (7.34%), followed by 
colorectal cancer (3.75%). Lung cancer and breast cancer had the highest average 
outpatient cost for each patient per year, while lung cancer, colorectal cancer, and 
gastric cancer had the highest average inpatient cost for each patient per year. The 
annual increase rates in the total cancer treatment cost for liver cancer, lung cancer, 
colorectal cancer, gastric cancer, and breast cancer were 10.70%, 11.61%, 16.73%, 
18.38%, and 17.21% respectively. We divided the cost structure of cancer treatments 
into chemotherapy, hormone therapy, and supportive treatment. The highest percent-
ages of chemotherapy and hormone therapy were for colorectal cancer (more than 
95%) and for breast cancer (more than 11%). On average, the annual increase rates 
in the cancer chemotherapy cost per patient for liver cancer, lung cancer, colorectal 
cancer, gastric cancer, and breast cancer were respectively 3.59%, 3.66%, 9.86%, 
16.78%, and 11.72%. CONCLUSIONS: This study showed a positive correlation 
between annual cancer patient number and NHI reimbursement, and an increasing 
trend for chemotherapy, hormone therapy, and supportive treatment. The results also 
showed that the number of the total amount of NHI reimbursement and the drug 
costs had increasing trends in these 7 years. This increased the ﬁ nancial burden of 
cancer patients and may alter the allocation of NHI resources.
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OBJECTIVES: New imaging tests such as computed tomography (CT), [18F]ﬂ uoro-
deoxyglucose-positron emission tomography (FDG-PET) scanning, and magnetic reso-
nance imaging (MRI) are not recommended for staging or follow-up of asymptomatic 
patients with EBC according to current guidelines. However, frequently these tests are 
requested even in the absence of a clinical indication. The purpose of this study was 
to evaluate how the availability of new imaging techniques has changed staging and 
follow-up modalities in EBC patients and to estimate its cost implications. METHODS: 
We analyzed clinical computerized information from 457 general practitioners assist-
ing an average of 630,000 inhabitants of the Campania region in the south of Italy. 
Incident EBC cases were selected and divided into calendar years from 2005 to 2008. 
The mean number of diagnostic tests prescribed per patient (N/Pt) and the mean costs 
per patient were evaluated during the ﬁ rst post-diagnosis year. The mean was com-
pared between each year using one-way analysis of variance. Costs were expressed in 
Euros (mean ± SD). RESULTS: We identiﬁ ed 576, 489, 474, and 497 newly diagnosed 
cases of EBC in 2005, 2006, 2007, and 2008, respectively. Overall, there was a sig-
niﬁ cant increase of the mean number of imaging tests prescribed per patient from 
2005 to 2008 (P < 0.0001). No change of the mean number of mammograms, bone 
scan, and chest x-ray requested per patient was observed. The mean costs per patient 
also signiﬁ cantly increased from c354.96 ± 581.32 in 2005 to c546.78 ± 837.36 in 
2008 (P = 0.004). CONCLUSIONS: CT, FDG-PET, and MRI employment for EBC 
patients in daily clinical practice has been steadily growing over the past 4 years with 
cost repercussions. However, there are no data to support their role in routine breast 
